Browse the evidence

Once-weekly tirzepatide (5, 10, or 15 mg) combined with lifestyle intervention produces statistically significant and clinically meaningful body weight reductions (up to -22.4%) and improvements in cardiometabolic risk factors in Japanese adults with obesity or overweight.

For Japanese adults with obesity or overweight, adding once-weekly tirzepatide to a standard lifestyle program (calorie deficit and exercise) leads to substantial weight loss (up to ~22%) and improves heart health markers like blood pressure and cholesterol. While injections are required, side effects like nausea are common but usually mild and temporary. This treatment is specifically approved and effective for this demographic, who may face higher health risks at lower BMIs compared to other ethnicities.

A 12-week low-glycemic index (LGI) diet produces significantly greater reductions in waist circumference, LDL cholesterol, non-HDL cholesterol, and leptin, along with greater increases in GLP-1, compared to a matched low-energy diet (LED) in women with excess body weight, without causing a decline in resting metabolic rate.

To improve your metabolic health and reduce belly fat, switch to a low-glycemic index diet for 12 weeks. Focus on eating foods with a GI of 55 or less freely, limit moderate-GI foods to two servings a day, and avoid high-GI foods. You do not need to strictly count calories; eat until you are satisfied. This approach has been shown to lower bad cholesterol, reduce belly fat more effectively than standard dieting, and improve hormonal markers like GLP-1 without slowing down your metabolism.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant weight loss in adults with obesity by acting centrally to reduce appetite and peripherally to delay gastric emptying.

Semaglutide 2.4mg weekly, combined with a 500 kcal daily deficit and 150 minutes of weekly activity, produces an average 14.8% body weight loss over 68 weeks. Expect gastrointestinal side effects like nausea, which are common but often manageable.

Sustained caloric restriction (800 kcal/day) followed by weight maintenance significantly reduces low-grade inflammation and improves lipid metabolism biomarkers in overweight/obese individuals.

For overweight individuals, a short period of strict caloric restriction (around 800 kcal/day) can significantly reduce chronic inflammation and improve lipid profiles. Crucially, maintaining the weight loss keeps these biological benefits active, suggesting that the initial 'shock' to the system has long-term metabolic advantages if the weight is kept off.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce HbA1c levels and body weight in patients with type 2 diabetes and obesity, with efficacy increasing from single agonists to dual (GLP-1/GIP) and triple (GLP-1/GIP/glucagon) agonists.

GLP-1 based medications (single, dual, and triple agonists) are highly effective for treating type 2 diabetes and obesity. They work by mimicking hormones that regulate blood sugar and appetite. Newer dual and triple agonists (like Tirzepatide and Retatrutide) show greater improvements in blood sugar and weight loss than older single-agonist drugs. Treatment is typically chronic, as stopping the medication often leads to weight regain. Options include weekly or daily injections, and some oral formulations are available for those who prefer to avoid needles. Consult a doctor to determine the best agent and dose for your specific health profile.

Combining amylin receptor agonist (cagrilintide) with GLP-1 RA (semaglutide) results in greater weight reduction than semaglutide monotherapy.

Combining cagrilintide 2.4 mg and semaglutide 2.4 mg, both injected once weekly, leads to 17.1% body weight loss over 20 weeks, which is significantly better than semaglutide alone (9.8%).

Semaglutide induces significant weight loss in type 2 diabetes patients across all BMI subgroups, with the effect being primarily direct rather than mediated by gastrointestinal side effects.

If you have type 2 diabetes, semaglutide (0.5mg or 1.0mg once weekly) will likely help you lose weight (2-6kg more than other common diabetes drugs), regardless of your starting weight. This weight loss happens directly through hormonal mechanisms, not just because you feel nauseous, although nausea is a common side effect.

High-dose GLP-1 receptor agonists (specifically semaglutide 2.4 mg) combined with lifestyle interventions produce significant, sustainable weight loss (-14.9% body weight) and improved glycemic control in patients with diabesity, making them superior to insulin and other antidiabetic agents regarding weight management.

If you have both diabetes and obesity, ask your doctor about GLP-1 agonists like semaglutide (2.4 mg). This treatment, combined with diet and exercise changes, has been shown to help patients lose nearly 15% of their body weight over 68 weeks while also controlling blood sugar. It is often more effective for weight loss than insulin, which tends to cause weight gain. Be aware that you might experience some nausea or vomiting at first, but these symptoms usually go away, and the long-term health benefits are significant.

Supplementation with 500 mg/day of Sensoril (aqueous ashwagandha extract) for 12 weeks significantly increases maximal strength (1-RM squat and bench press) and aerobic endurance (7.5 km cycling time trial) in recreationally active men undergoing resistance training compared to placebo.

If you are a man who lifts weights recreationally, taking 500 mg of Sensoril (a specific ashwagandha extract) daily for 12 weeks, alongside your normal 4-day/week resistance training, can help you gain more strength and improve your aerobic endurance than training alone. Ensure you are healthy, normotensive, and not taking other ergogenic supplements before starting.

Individuals with elevated fasting plasma glucose (prediabetes or diabetes) achieve significantly greater weight loss on low-carbohydrate or high-fiber/low-glycemic-load diets compared to those with normal fasting plasma glucose, who show minimal differential response to these dietary compositions.

If you are overweight and have high fasting blood sugar (prediabetes or diabetes), you are likely to lose more weight by choosing a diet lower in carbohydrates or higher in fiber/low glycemic load. If your blood sugar is normal, the specific type of healthy diet matters less for weight loss magnitude, and adherence is the primary driver.

The Mediterranean diet reduces visceral adiposity and insulin resistance, key drivers of metabolic syndrome.

Focus on reducing visceral fat by following a Mediterranean diet rich in fiber and healthy fats. This helps improve insulin sensitivity and reduces the risk of metabolic syndrome, even if total body weight changes are gradual.

GLP-1 receptor agonists (specifically liraglutide and semaglutide) produce the greatest weight loss among anti-diabetic medications, with effects classified as strong (>5% reduction), whereas DPP-4 inhibitors and alpha-glucosidase inhibitors (acarbose) produce only mild or neutral effects.

If you have Type 2 Diabetes and struggle with weight loss, GLP-1 receptor agonists (like liraglutide or semaglutide) are currently the most effective pharmacological option for reducing body weight, significantly outperforming older drugs like DPP-4 inhibitors or acarbose. While these drugs may cause initial gastrointestinal side effects, their ability to produce strong weight loss (>5%) makes them a superior choice for managing obesity in diabetic patients compared to weight-neutral or weight-gain-inducing alternatives like sulfonylureas or insulin.

High intake of fructose and high-glycemic carbohydrates promotes obesity and insulin resistance through de novo lipogenesis, ectopic lipid deposition, and inflammatory pathways, whereas high fiber intake improves metabolic health via short-chain fatty acid production and microbiome modulation.

Prioritize whole, fiber-rich carbohydrates (vegetables, whole grains, legumes) and minimize added sugars, especially fructose and high-fructose corn syrup found in processed foods and beverages. The type of carbohydrate matters more than the total amount for metabolic health.

Restricting dietary carbohydrate to less than 130 grams per day improves metabolic health markers (insulin sensitivity, lipid profile, blood pressure) in individuals with insulin resistance, type 2 diabetes, or metabolic syndrome, often superior to low-fat diets.

To improve metabolic health, especially if you have insulin resistance or type 2 diabetes, reduce your daily carbohydrate intake to under 130 grams (or under 50 grams for a ketogenic effect). Ensure you eat adequate protein (1.2-2.0 g/kg of adjusted body weight) and replace lost electrolytes (sodium, potassium) to avoid side effects. This approach is more effective for metabolic markers than traditional low-fat diets.

GLP-1 receptor agonists (GLP-1 RAs) promote weight loss and improve glycemic control through multiple mechanisms including increased satiety, slowed gastric emptying, and enhanced insulin secretion, with semaglutide 2.4 mg showing the highest efficacy.

GLP-1 receptor agonists like semaglutide are highly effective for weight loss and blood sugar control. Semaglutide 2.4 mg taken once weekly (either orally or by injection) resulted in an average loss of 15.3 kg over 68 weeks in clinical trials. This is significantly more effective than placebo. These drugs work by increasing satiety, slowing digestion, and improving insulin function. They are suitable for adults with obesity or type 2 diabetes.

Resistance exercise combined with protein-carbohydrate feeding induces a sustained translocation of mTORC1 to the cell periphery (sarcolemma) in human skeletal muscle, which is associated with prolonged S6K1 kinase activity compared to feeding alone.

To maximize the duration of muscle-building signals, combine resistance training with protein intake. While eating protein alone triggers some signals, adding resistance exercise keeps the key growth machinery (mTORC1) active at the muscle cell membrane for longer (up to 3 hours post-workout), potentially supporting better muscle growth over time.

Tirzepatide 15 mg provides superior HbA1c reduction and bodyweight loss compared to other GLP-1RA-based therapies, including high-dose GLP-1RA and GLP-1RA plus basal insulin fixed-ratio combinations, without increasing the risk of hypoglycemia.

For patients with type 2 diabetes seeking maximum glycemic control and weight loss, tirzepatide 15 mg is the most effective GLP-1RA-based therapy available, outperforming high-dose GLP-1RAs and insulin combinations without increasing hypoglycemia risk.

Consuming 25g of potato protein isolate twice daily (totaling 1.6g protein/kg/day) stimulates muscle protein synthesis at rest and further augments it when combined with resistance exercise in young women.

If you are a young woman looking to build muscle, consuming 25g of potato protein isolate twice a day (totaling 1.6g of protein per kg of body weight) will stimulate muscle growth even when you are not exercising. Adding resistance exercise will boost this effect further. This makes potato protein a viable, high-quality alternative to animal-based proteins for muscle building.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, achieves greater glycemic control and weight loss compared to isolated GLP-1 receptor agonism.

For individuals with Type 2 Diabetes or obesity who need more than standard GLP-1 medications, Tirzepatide is a newer option that targets two hormone receptors (GIP and GLP-1). Clinical trials show it can lower blood sugar by more than 2% and achieve weight loss exceeding 15%, which is greater than what is typically seen with GLP-1-only drugs.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, induces substantial weight loss and improves histological markers of metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis in patients with type 2 diabetes and obesity.

If you have MASH and obesity, tirzepatide is a once-weekly injection that helps you lose weight and improves liver health markers. It starts at a low dose and increases slowly to minimize side effects. You should also follow diet and exercise advice provided by your care team.

Tirzepatide produces significantly greater weight loss and glycemic improvement than semaglutide when used at comparable maintenance dosages and adherence levels.

If you are choosing between Semaglutide and Tirzepatide, Tirzepatide tends to produce greater weight loss (approx. 12% vs 8% average in this study). However, this benefit is only realized if you stay on the medication. If you struggle with side effects or cost, switching drugs may not solve the problem if you end up discontinuing.

Consuming protein and/or fiber before carbohydrates (meal sequencing) enhances GLP-1 secretion, delays gastric emptying, and improves postprandial glucose and lipid metabolism compared to consuming carbohydrates first.

To get more out of your meals, try eating your protein and vegetables before your carbohydrates (like rice, pasta, or bread). This simple change in order triggers your gut to release more satiety hormones (GLP-1) and slows down digestion, leading to better blood sugar control and less fat storage potential.

Prevention or delay of type 2 diabetes through intensive lifestyle intervention or metformin is associated with a lower prevalence of microvascular complications (retinopathy, nephropathy, neuropathy) compared to those who progress to diabetes.

Avoiding or delaying the onset of type 2 diabetes significantly reduces your risk of developing serious microvascular complications like eye, kidney, and nerve damage. This benefit is observed even if you don't take medication, as long as you prevent or delay diabetes.

A well-designed vegan diet is an effective first-line treatment for Type 2 Diabetes, improving glycemia, insulin sensitivity, and beta-cell function.

Adopt a well-designed vegan diet to manage Type 2 Diabetes. This approach can significantly improve blood sugar control, insulin sensitivity, and beta-cell function, often more effectively than conventional diabetes diets.